OCEA (Ocean Biomedical) FCF Margin %: 0.00% (As of Mar. 2025)


What is Ocean Biomedical FCF Margin %?

Ocean Biomedical OCEA +150.00% FCF Margin % is 0.00% as of Mar. 2025.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Ocean Biomedical's Free Cash Flow for the three months ended in Mar. 2025 was $-0.36 Mil. Ocean Biomedical's Revenue for the three months ended in Mar. 2025 was $0.00 Mil. Therefore, Ocean Biomedical's FCF Margin % for the quarter that ended in Mar. 2025 was 0.00%.

As of today, Ocean Biomedical's current FCF Yield % is -3,492.24%.

The historical rank and industry rank for Ocean Biomedical's FCF Margin % or its related term are showing as below:


OCEA's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -85.21
* Ranked among companies with meaningful FCF Margin % only.

Ocean Biomedical FCF Margin % Related Terms

Ocean Biomedical FCF Margin % Historical Data

* Premium members only.

The historical data trend for Ocean Biomedical's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ocean Biomedical FCF Margin % Chart

Ocean Biomedical Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
FCF Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Ocean Biomedical Quarterly Data
Dec19 Mar20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

OCEA vs SIGY, ENDV, SCPX: FCF Margin % Comparison

For the Biotechnology subindustry, Ocean Biomedical's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ocean Biomedical FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocean Biomedical's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Ocean Biomedical's FCF Margin % falls into.


Ocean Biomedical FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Ocean Biomedical's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-4.18/0
= %

Ocean Biomedical's FCF Margin for the quarter that ended in Mar. 2025 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2025 )/Revenue (Q: Mar. 2025 )
=-0.356/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Ocean Biomedical (OCEA) has a FCF Margin % of 0.00% as of Mar. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Ocean Biomedical and its competitors.
Is Ocean Biomedical's FCF Margin % too high?
Ocean Biomedical's current FCF Margin % is 0.00%.
How does Ocean Biomedical's FCF Margin % compare to SIGY and ENDV?
Ocean Biomedical's FCF Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Ocean Biomedical and its competitors. Ocean Biomedical's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ocean Biomedical stock overvalued right now?
Ocean Biomedical (OCEA) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Ocean Biomedical (OCEA), the current FCF Margin % is 0.00% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ocean Biomedical Business Description

Address 55 Claverick Street, Room 325, Providence, RI, USA, 02903
Ocean Biomedical Inc is a biopharmaceutical company that is focused on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.